Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders
The PLA2R1 gene encodes a secretory phospholipase. Autoantibodies angainst this protein were detected in membranous glomerulonephritis and polymorphisms in this gene show a strong correlation with idiopathic membranous nephropathy.
| Clinic | Method | Carrier testing |
| Turnaround | 5 days | |
| Specimen type | genomic DNA |
| Clinic | Method | Genomic sequencing of the entire coding region |
| Turnaround | 25 days | |
| Specimen type | genomic DNA |
| 1. |
Debiec H et al. (2014) Immunopathogenesis of membranous nephropathy: an update. 
|
| 2. |
Ancian P et al. (1995) The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization.
|
| 3. |
Beck LH et al. (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
|
| 4. |
Wuttke M et al. (2016) Insights into kidney diseases from genome-wide association studies.
|
| 5. |
Sinico RA et al. (2016) Immunology of membranous nephropathy: from animal models to humans.
|
| 6. |
Radice A et al. (2016) Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
|
| 7. |
Li Y et al. (2016) Single-nucleotide polymorphisms in the PLA2R1 gene are associated with systemic lupus erythematosus and lupus nephritis in a Chinese Han population.
|
| 8. |
Hihara K et al. (2016) Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy.
|
| 9. |
Gentile G et al. (2016) Novel Biomarkers for Renal Diseases? None for the Moment (but One).
|
| 10. |
Francis JM et al. (2016) Membranous Nephropathy: A Journey From Bench to Bedside.
|
| 11. |
Ruggenenti P et al. (2015) Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
|
| 12. |
Ronco P et al. (2015) Pathophysiological advances in membranous nephropathy: time for a shift in patient's care.
|
| 13. |
Ronco P et al. (2015) Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients.
|
| 14. |
Li ZQ et al. (2015) Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: A meta-analysis of Chinese adults.
|
| 15. |
Lai WL et al. (2015) Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment.
|
| 16. |
None (2015) Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
|
| 17. |
Smyth LJ et al. (2014) Genetic and epigenetic factors influencing chronic kidney disease.
|
| 18. |
Lv J et al. (2013) Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy.
|
| 19. |
NCBI article NCBI 22925
|
| 20. |
OMIM.ORG article Omim 604939
|
| 21. |
Wikipedia article Wikipedia EN (PLA2R1)
|
 |
Copyright © 2005-2025 by Center for Nephrology and Metabolic Disorders, Dr. Mato Nagel, MD Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Germany, Tel.: +49-3576-287922, Fax: +49-3576-287944 Sitemap | Webmail | Disclaimer | Privacy Issues | Website Credits |
